TY - CHAP
T1 - Opportunistic autoimmune disorders
T2 - From immunotherapy to immune dysregulation
AU - Kong, Yi Chi M.
AU - Wei, Wei Zen
AU - Tomer, Yaron
PY - 2010/1/10
Y1 - 2010/1/10
N2 - Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.
AB - Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-α (also used to treat hepatitis C patients) and interferon-β; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described.
KW - Autoimmunity
KW - Immune dysregulation
KW - Immunotherapeutic sequelae
KW - Immunotherapy
KW - Opportunistic autoimmunity
UR - http://www.scopus.com/inward/record.url?scp=75749141271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75749141271&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2009.05138.x
DO - 10.1111/j.1749-6632.2009.05138.x
M3 - Chapter
C2 - 20146718
AN - SCOPUS:75749141271
SN - 9781573317795
T3 - Annals of the New York Academy of Sciences
SP - 222
EP - 236
BT - The Year in Immunology 2
PB - Blackwell Publishing Inc.
ER -